Why did 42C.SI stock spike pre-market today?

The spike reflects heavy trading interest—**45,100,500** shares versus average **13,951,495**—and momentum chasing after a gap from **S$0.145** to **S$0.188**. No confirmed company release was in public feeds; volume suggests speculative buying or repositioning ahead of catalysts.

What is Meyka AI's short-term price view for 42C.SI stock?

Meyka AI's model projects **S$0.27** in three months (implied +43.62%). This is model-based and not a guarantee; traders should use stops and watch clinical or corporate news that can change the outlook quickly.

Is 42C.SI stock a buy for long-term investors?

Current fundamentals show negative earnings and a weak liquidity ratio; Meyka AI gives a **C+ (HOLD)**. Long-term buyers should wait for clearer clinical progress or improved financials before adding significant exposure.

How should traders manage risk on 42C.SI stock after the volume spike?

Use tight stop-losses and size positions smaller than usual due to high volatility and overbought indicators (RSI **80.23**). Consider scaling out into strength and monitor average volume and newsflow closely.

SG Stocks

29.66% pre-market surge: 42C.SI iX Biopharma Ltd. SES 13 Jan 2026: volume spikes

ByDanny Kontos January 12, 2026January 12, 2026

42C.SI stock jumped 29.66% pre-market to S$0.188 on 13 Jan 2026, driven by an intraday volume surge of 45,100,500 shares versus an average of 13,951,495. This high-volume move on the Singapore Exchange (SES) follows a gap from the previous close of S$0.145 and pushed the trading range to a day high of S$0.195. Traders should note the large relative volume 3.03x and stretched technicals; we examine fundamentals, Meyka AI grade and model forecasts to frame short-term opportunities and risks for iX Biopharma Ltd.